Comparative Pharmacology
Head-to-head clinical analysis: PROCAINAMIDE HCL versus QUINAGLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAINAMIDE HCL versus QUINAGLUTE.
PROCAINAMIDE HCL vs QUINAGLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Class Ia antiarrhythmic agent; binds to sodium channels and inhibits the fast inward sodium current, slowing phase 0 depolarization and prolonging the action potential duration. Also exhibits anticholinergic and negative inotropic effects.
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
324-648 mg orally every 8-12 hours; extended-release formulation (quinidine gluconate).
None Documented
None Documented
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Terminal elimination half-life is 5-7 hours in adults with normal renal function. In hepatic impairment, half-life may increase to 12-24 hours; in severe renal impairment (CrCl <10 mL/min), half-life may exceed 24 hours.
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of total clearance. Biliary/fecal excretion contributes about 20-30%. Acidic urine increases renal clearance.
Category A/B
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)